For the past year, the pharmaceutical industry has been bracing for the Sunshine Act, a provision of health care reform that requires drug makers to gather and report payments and gifts to physicians. The disclosures, which will be made public on a federal government web site, are being submitted in stages, but a preliminary round that recently ended suggests that drug makers are uneasy.. In a recent survey, drug makers came across payments that raised compliance concerns; expressed confusion about assigning financial values to certain items given physicians; encountered formatting problems that caused submissions to be rejected, and worry there will be discrepancies as more granular reporting occurs in the second phase that started this month.